Integrated Model for the Prevention of Anal Cancer Using Screen and Treat for High-grade Intraepithelial Lesions (IMPACT)

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The study is a feasibility pilot trial testing 2 types of training protocols on a single physician. The first training protocol is the current standard and was developed in high-income settings. The second training protocol will be developed so tailored to the Nigerian setting. Investigators will test if the physician performs differently in their ability to conduct anal cancer screening and treatment between the 2 training protocols.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Possess a medical degree in medical sciences (MBBS or equivalent)

• At least 2-5 years of experience working with clinical HIV/AIDS community

• Must be registered with the medical and dental council of Nigeria

• Possess a current medical practicing license

• Willing to work with the Sexual Gender Minority Community

Locations
Other Locations
Nigeria
International Center for Advocacy on Right to Health (ICARH)
RECRUITING
Abuja
Contact Information
Primary
Rebecca Nowak, PhD
rnowak@ihv.umaryland.edu
4107064642
Backup
Sylvia Adebajo
SAdebajo@mgic.umaryland.edu
Time Frame
Start Date: 2023-05-02
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 1
Treatments
Experimental: Enhanced Training on screening and treatment of HSIL (e-STH)
Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
No_intervention: Standard Screening and treatment of HSIL
The standard screening and treatment of HSIL outlined by the International Anal Neoplasia Society
Sponsors
Collaborators: National Cancer Institute (NCI)
Leads: University of Maryland, Baltimore

This content was sourced from clinicaltrials.gov